- Home
- EDIT vs LFCR Comparison
EDIT vs LFCR Comparison
Compare EDIT & LFCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDIT
- LFCR
- Stock Information
- Founded
- EDIT 2013
- LFCR 1986
- Country
- EDIT United States
- LFCR United States
- Employees
- EDIT N/A
- LFCR N/A
- Industry
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- LFCR Biotechnology: Pharmaceutical Preparations
- Sector
- EDIT Health Care
- LFCR Health Care
- Exchange
- EDIT Nasdaq
- LFCR Nasdaq
- Market Cap
- EDIT 263.7M
- LFCR 308.8M
- IPO Year
- EDIT 2016
- LFCR N/A
- Fundamental
- Price
- EDIT $2.28
- LFCR $7.69
- Analyst Decision
- EDIT Buy
- LFCR Buy
- Analyst Count
- EDIT 12
- LFCR 4
- Target Price
- EDIT $6.20
- LFCR $8.00
- AVG Volume (30 Days)
- EDIT 2.2M
- LFCR 122.7K
- Earning Date
- EDIT 08-19-2025
- LFCR 08-07-2025
- Dividend Yield
- EDIT N/A
- LFCR N/A
- EPS Growth
- EDIT N/A
- LFCR N/A
- EPS
- EDIT N/A
- LFCR N/A
- Revenue
- EDIT $35,837,000.00
- LFCR $130,309,000.00
- Revenue This Year
- EDIT N/A
- LFCR $1.64
- Revenue Next Year
- EDIT N/A
- LFCR $2.91
- P/E Ratio
- EDIT N/A
- LFCR N/A
- Revenue Growth
- EDIT N/A
- LFCR 7.23
- 52 Week Low
- EDIT $0.91
- LFCR $3.68
- 52 Week High
- EDIT $4.90
- LFCR $8.85
- Technical
- Relative Strength Index (RSI)
- EDIT 43.28
- LFCR 55.86
- Support Level
- EDIT $2.37
- LFCR $7.13
- Resistance Level
- EDIT $2.67
- LFCR $7.51
- Average True Range (ATR)
- EDIT 0.23
- LFCR 0.35
- MACD
- EDIT -0.08
- LFCR 0.03
- Stochastic Oscillator
- EDIT 5.37
- LFCR 88.79
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About LFCR Lifecore Biomedical Inc.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers differentiated capabilities in the development, filling, and finishing of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid. Lifecore recognizes revenue in two different product categories, CDMO and fermentation.